证券日报网讯11月13日晚间，华润双鹤（600062）发布公告称，近日，华润双鹤药业股份有限公司(以 下简称"公司")控股子公司双鹤天安药业(贵州)股份有限公司(以下简称"双鹤天安")收到贵州省药品监督 管理局颁发的《药品GMP符合性检查告知书》。 ...

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

华润双鹤药业股份有限公司 关于控股子公司双鹤天安药业(贵州)股份有限公司 通过GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")控股子公 司双鹤天安药业(贵州)股份有限公司(以下简称"双鹤天安")收到贵 州省药品监督管理局颁发的《药品 GMP 符合性检查告知书》(编号： 黔 20250059)，现将相关情况公告如下： 一、GMP 检查相关信息 被检查单位名称：双鹤天安药业(贵州)股份有限公司 检查地址：贵州省贵阳市乌当区高新路 25 号 检查范围及相关车间、生产线： 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－096 片剂[二甲双胍恩格列净片(Ⅰ)(每片含盐酸二甲双胍 500mg 与恩 格列净 5mg)，综合车间(四)片剂生产线，自行生产] 检查时间：2025 年 10 月 15 日至 10 月 17 日 结论：符合 本次检查是二甲双胍恩格列净片(Ⅰ)上市前的首次药品 GMP 符合 性检查。上述检查项目是在原有厂房、设备情况下的检 ...

Core Viewpoint - China Resources Double Crane Pharmaceutical (华润双鹤) announced that its subsidiary, Double Crane Tianan Pharmaceutical (贵州双鹤天安药业), received a GMP compliance inspection notice from the Guizhou Provincial Drug Administration, indicating regulatory approval for its production line [1] Group 1: Company Information - The subsidiary involved is Double Crane Tianan Pharmaceutical, which is located in Guizhou [1] - The production line is designed for the manufacturing of Metformin and Ertugliflozin tablets, with a capacity of 500 million tablets per year [1] Group 2: Regulatory Approval - The notice received is titled "Drug GMP Compliance Inspection Notice" with the reference number: 黔20250059 [1] - The inspection covered the tablet production line and related workshops, confirming compliance with GMP standards [1]

Core Viewpoint - China Resources Double Crane Pharmaceutical (600062.SH) announced that its subsidiary, Double Crane Tianan Pharmaceutical (Guizhou) Co., Ltd., received a GMP compliance inspection notice from the Guizhou Provincial Drug Administration [1] Group 1: Company Developments - The inspection notice (No. 黔20250059) pertains to the production of Metformin and Ertugliflozin tablets (Ⅰ), with each tablet containing 500mg of Metformin Hydrochloride and 5mg of Ertugliflozin [1] - The production line involved in the inspection is designed with an annual capacity of 500 million tablets [1]

华润双鹤公告，控股子公司双鹤天安药业(贵州)股份有限公司收到贵州省药品监督管理局颁发的《药品 GMP符合性检查告知书》。检查范围为片剂，检查时间为2025年10月15日至10月17日，结论为符合。 ...

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]

Core Viewpoint - The article discusses the establishment of significant investment funds by China Resources Double Crane and China Resources Pharmaceutical, focusing on synthetic biology and innovative pharmaceuticals, indicating a strategic shift towards high-growth sectors in the biomanufacturing industry [2][3]. Investment Fund Establishment - China Resources Double Crane and China Resources Pharmaceutical announced the formation of a 500 million RMB fund, with a commitment of 123 million RMB from the group, representing 24.6% of the total fund [2]. - China Resources Double Crane also established the "China Resources Double Crane Industry Fund," committing up to 83 million RMB, approximately 16.6% of the total fund, aimed at optimizing strategic layout in synthetic biology [3]. Collaboration and Partnerships - The funds involve collaboration with local governments and multiple investors, including 11 limited partners (LPs) such as various China Resources entities and Chengdu local government funds, collectively forming a 1 billion RMB investment fund [3][4]. - The partnership includes significant contributions from local government funds and private enterprises, showcasing a collaborative approach to investment in the biomanufacturing sector [4]. Strategic Focus on Synthetic Biology - China Resources Double Crane has previously invested 502 million RMB to acquire a 50.11% stake in Shenzhou Biology, enhancing its capabilities in the biomanufacturing field [5]. - The establishment of a synthetic biology research institute in 2023 indicates a commitment to developing a comprehensive R&D, pilot testing, and industrialization system, focusing on industrial enzymes and microorganisms [5]. Research and Development Initiatives - The company has developed seven technology platforms in synthetic biology, with over ten ongoing projects, leveraging expertise from seasoned scientists with experience in major corporations [5].

Core Viewpoint - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony highlighted the achievements of companies in the capital market, with Huaren Shuanghe's chairman receiving the "Golden Bull Entrepreneur Innovation Award" for his contributions to innovation and value creation [1][2]. Group 1: Event Overview - The Golden Bull Award, established in 1999, aims to create a credible platform for showcasing listed companies in China's capital market, emphasizing transparency and scientific evaluation [1]. - The award recognizes companies with exemplary governance, performance growth, and positive contributions to shareholders and society [1]. Group 2: Company Innovations and Achievements - During the "14th Five-Year Plan" period, the company adopted a dual-driven approach of "R&D innovation + external development," focusing on developing high-quality drugs that meet clinical needs [2]. - The successful introduction of the innovative drug "Subi One" exemplifies the company's commitment to clinical value and innovation [2]. - The company aims to establish itself as "China's prescription drug number one brand" and is determined to represent state-owned enterprises in innovation and transformation [2]. - In the latest 2025 ranking of China's top 100 chemical drug companies, Huaren Shuanghe advanced to the 13th position, showcasing its competitive edge in a crowded market [2].